Amicus Therapeutics ApS: Financial statements 2019
CVR: 39359340
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Amicus Therapeutics ApS (CVR 39359340) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 2,019,085 and a net result of DKK 84,291 compared with DKK 73,533 the year before. That is an increase of 2% compared with the year before. Equity in the 2019 report amounted to DKK 207,824. The solvency ratio was 41.8%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 2,019,085
- Profit/Loss
- DKK 84,291
- Equity
- DKK 207,824
- Total Assets
- DKK 496,746
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 2 mio. | 84 t. | 208 t. | 2 |
| 2018 | - | 2 mio. | 74 t. | 124 t. | 2 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Amicus Therapeutics ApS has published its interim report for the period February 23, 2018 – December 31, 2018.
As of February 12, 2019, Detlef Wolff has left the board of directors of Amicus Therapeutics ApS.
About Amicus Therapeutics ApS
Amicus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Richard Gideon Morris. The board consists of Richard Gideon Morris (chair), Brian Keogh and Steven John Green. The company is owned by Amicus Therapeutics UK Ltd.. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 1,441,140 and a net result of DKK 115,004 compared with DKK 16,475 the year before. Equity in the 2025 report amounted to DKK 424,641.